期刊
DIAGNOSTICS
卷 11, 期 5, 页码 -出版社
MDPI
DOI: 10.3390/diagnostics11050844
关键词
non-Hodgkin's lymphoma; chimeric antigen receptor T cell therapy; TP53 mutation; circulating tumor DNA; droplet digital PCR
资金
- National Natural Science Foundation of China [81700160, 81974005, 81873444, 81830008]
This study found that TP53-mutated ctDNA levels can serve as a prognostic marker in NHL patients following CAR T-cell therapy, with higher ctDNA levels being associated with poorer outcomes.
Chimeric antigen receptor T (CAR T) cell immunotherapy has shown remarkable efficacy in non-Hodgkin's lymphoma (NHL) patients. Minimal residual disease (MRD) monitoring in NHL is essential after CAR T cell therapy, which can be achieved by monitoring circulating tumor DNA (ctDNA). The mutation of TP53 in NHL has been suggested to be associated with a poor prognosis. However, whether TP53-mutated ctDNA can be used as a biomarker remains undetermined. In this study, a total of 40 patients with mutated TP53 who received CAR T cell treatment were analyzed, and specific probes targeting 29 different TP53 mutation sites in the 40 patients were designed and verified. Then, the presence of TP53-mutated ctDNA in longitudinal plasma samples was tracked by droplet digital PCR. Patients were stratified into two groups, favorable or unfavorable, based on their highest ctDNA level using a MAF cutoff of 3.15% according to the ROC curve. The unfavorable group had significantly worse PFS than the favorable group (p < 0.001). Our results suggest that patients with mutated TP53 with a favorable ctDNA profile in the first trimester have better prognostic outcomes than patients with an unfavorable profile, and ctDNA can be a reliable predictor of the subsequent clinical outcome.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据